[1]牛 悦,白建平,卢建跃.HER-2阳性胃癌的研究进展[J].医学信息,2019,(01):44-46.[doi:10.3969/j.issn.1006-1959.2019.01.015]
 NIU Yue,BAI Jian-ping,LU Jian-yue.Progress in Research of HER-2 Positive Gastric Cancer[J].Medical Information,2019,(01):44-46.[doi:10.3969/j.issn.1006-1959.2019.01.015]
点击复制

HER-2阳性胃癌的研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年01期
页码:
44-46
栏目:
综述
出版日期:
2019-01-01

文章信息/Info

Title:
Progress in Research of HER-2 Positive Gastric Cancer
文章编号:
1006-1959(2019)01-0044-03
作者:
牛 悦白建平卢建跃
解放军第二五四医院普外科,天津 300143
Author(s):
NIU YueBAI Jian-pingLU Jian-yue
General Surgery,the 254th Hospital of Chinese PLA,Tianjin 300143,China
关键词:
人类表皮生长因子受体2胃癌靶向治疗
Keywords:
Human epidermal growth factor receptor-2Gastric cancerTargeted therapy
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2019.01.015
文献标志码:
A
摘要:
胃癌是我国最常见的消化道恶性肿瘤之一,随着我国社会经济的发展、人们食物谱的改变,我国的胃癌发病率呈显著上升趋势。人类表皮生长因子受体2(HER-2)是一种原癌基因,在部分胃癌患者中存在高表达,针对HER-2的靶向治疗,可使HER-2阳性的晚期胃癌患者获得显著的生存收益。ToGA研究是胃癌靶向治疗史上的一座里程碑,它首次在大规模样本中证实看联合应用化疗药及曲妥珠单抗可有效延长患者生存期。本文就HER-2阳性胃癌的研究进展作一综述。
Abstract:
Gastric cancer is one of the most common malignant tumors of the digestive tract in China. With the development of China's social economy and the changes in people's food spectrum, the incidence of gastric cancer in China has shown a significant upward trend. Human epidermal growth factor receptor 2 (HER-2) is a proto-oncogene that is highly expressed in some patients with gastric cancer. Targeted therapy against HER-2 can significantly improve HER-2 positive patients with advanced gastric cancer. Survival gains. The ToGA study is a milestone in the history of targeted therapy for gastric cancer. It was first demonstrated in large-scale samples that the combination of chemotherapeutic drugs and trastuzumab can effectively prolong patient survival. This article reviews the research progress of HER-2 positive gastric cancer.

参考文献/References:

[1]An E,Ock CY,Kim TY,et al.Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment[J].Annals of Oncology,2017,28(1): 110-115.
[2]Wang H,Wang W,Xu Y,et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in HER2-positive gastric cancer cells[J].Cancer Science,2017,108(7):1458-1468.
[3]Shi HZ,Wang YN,Huang XH,et al.Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer[J].World Journal of Gastroenterology,2017,23(10):1836-1842.
[4]Shin SH,Park SS,Ju EJ,et al.Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer[J].Anticancer Research,2018,38(1):287-293.
[5]Uguen A.About HER2 monitoring using liquid biopsies in patients with gastric cancer[J].Gastric Cancer,2017,20(6):1011-1012.
[6]Liu D,Li X,Chen C,et al.Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles[J].Oncology Letters,2018,15(5):8079-8087.
[7]Ji C,Zhang Q,Guan W,et al.Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers[J].Oncotarget,2017,8(30):49293-49302.
[8]Qiu MZ,Shi SM,Chen M,et al.Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer[J].Journal of Cancer,2017,8(17):3531-3537.
[9]Zhang X,Yao J,Guo K,et al.The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin[J].Oncotarget,2018,9(2):2105-2119.
[10]Cho JH,Lim JY,Cho JY.Survival analysis based on human epidermal growth factor 2 status in stage Ⅱ-Ⅲ gastric cancer[J].World Journal of Gastroenterology,2017,23(41):7407-7414.
[11]Palle J,Tougeron D,Pozet A.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study[J].Oncotarget,2017,8(60):101383-101393.
[12]王昆宇.1363例胃癌HER-2/neu表达临床流行病学研究[D].吉林大学,2013.
[13]Neves Filho EHC,Pires APB,de Sant'Ana RO,et al.The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma[J].Apmis,2018,126(5):389-395.
[14]Lee JS,Kim SH,Im SA,et al.Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics[J].Korean Journal of Radiology,2017,18(5):809-820.
[15]Hofmann M,Stoss O,Shi D,et al.Assessment of a HER2 scoring system for gastric cancer: results from a validation study[J].Histopathology,2010,52(7):797-805.
[16]《胃癌HER检测指南》编写组.胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557.
[17]《胃癌HER检测指南》专家组.胃癌HER2检测指南(2016版)[J].中华病理学杂志,2016,45(8):528-532.
[18]Kurokawa Y,Sugimoto N,Miwa H,et al.Phase Ⅱ study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)[J].British Journal of Cancer,2014,110(5):1163-1168.
[19]Nishikawa K,Takahashi T,Takaishi H,et al.Phase Ⅱ study of the effectiveness and safety of trastuzumab and paclitaxel for taxane-and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)[J].International Journal of Cancer,2016,140(1):188-196.
[20]Yoshioka T,Shien K,Namba K,et al.Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer[J].Cancer Science,2018,109(4):1166-1176.
[21]Dai GH,Shi Y,Chen L,et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology,2012,59(120):2439-2444.
[22]Mitsui Y,Sato Y,Miyamoto H,et al.Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy[J].Cancer Chemotherapy & Pharmacology,2015,76(2):375-382.
[23]Al-Batran SE,Hozaeel W,Jager E.Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases[J].Onkologie,2012,35(9):505-508.
[24]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[25]Liang JW,Zhang JJ,Zhang T,et al.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature[J].Tumor Biology,2014,35(5):4849-4858.
[26]Grabsch H,Sivakumar S,Gray S,et al.HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series[J].Cell Oncol,2010,32(1-2):57-65.
[27]Kang YK,Rha SY,Tassone P,et al.A phase Ⅱ a dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer[J].British Journal of Cancer,2014,111(4):660-666.
[28]Satoh T,Xu RH,Chung HC,et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase Ⅲ study[J].Journal of Clinical Oncology,2016,32(19):2039-2049.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
 YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,(01):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
 RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Medical Information,2018,(01):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
 DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Medical Information,2018,(01):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
 PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Medical Information,2018,(01):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(01):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[6]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
 LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Medical Information,2018,(01):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[7]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
 MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Medical Information,2018,(01):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[8]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
 ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Medical Information,2018,(01):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[9]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
 WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Medical Information,2018,(01):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
[10]张 印,张 军.进展期胃癌淋巴结清扫研究进展[J].医学信息,2019,(07):57.[doi:10.3969/j.issn.1006-1959.2019.07.018]
 ZHANG Yin,ZHANG Jun.Progress in Lymph Node Dissection of Advanced Gastric Carcinoma[J].Medical Information,2019,(01):57.[doi:10.3969/j.issn.1006-1959.2019.07.018]

更新日期/Last Update: 2019-01-22